【摘要】 目的 探讨CHOP(环磷酰胺+多柔比星+长春新碱+泼尼松)方案联合沙利度胺治疗B细胞非霍奇金淋巴瘤(NHL)的临床疗效，并分析影响预后的相关因素。方法 回顾性分析2014年9月—2017年10月本院收治的112例B细胞非霍奇金淋巴瘤患者的临床资料，按照治疗方案不同将其分为治疗组和对照组两组，每组各56例。对照组采用CHOP方案治疗，治疗组采用CHOP联合沙利度胺方案治疗。观察两组患者的临床疗效、不良反应发生情况及3年生存率，分析影响预后的因素。结果 治疗组和对照组患者化疗后客观缓解率(ORR)分别为76.8%和53.6%,差异具有统计学意义(P<0.05);治疗组与对照组的不良反应发生情况对比，差异无统计学意义(P>0.05);治疗组患者中位生存时间及生存率为33.0个月和41.07%,而对照组的中位生存期为30.0个月，3年总生存率为32.14%,差异无统计学意义(P>0.05);B细胞NHL患者的预后与Ann Arbor分期、IPI指数、B症状和近期疗效等因素有关(P<0.05)。结论 CHOP方案联合沙利度胺治疗B细胞NHL的疗效及耐受性良好，可依据Ann Arbor分期、IPI指数、B症状和近期疗效判断B细胞NHL的远期预后。更多还原

【Abstract】 Objective To explore the clinical efficacy of CHOP regimen(cyclophosphamide + doxorubicin + vincristine + prednisone) combined with thalidomide in the treatment of B cell non-Hodgkin’s lymphoma, and analyze the factors affecting the prognosis of patients.Methods The clinical data of 112 patients suffered with B cell non-Hodgkin’s lymphoma who received treatment in Xinxiang first people’s hospital from Sep 2014 to Oct 2017 were retrospectively analyzed. The patients were divided into a treatment group(56 cases) and a control group( 56 cases) according to different therapies scheme. Patients in control group received CHOP chemotherapy,and the patients in treatment group received the scheme of CHOP combined with thalidomide. The clinical efficacy,adverse reactions and 3-year survival rate were compared between the two groups,and the influencing factors of prognosis were analyzed. Results The objective remission rate was 76. 8% in the treatment group after chemotherapy,which was higher than53.6% of the control group,the difference was statistically significant( P < 0. 05). There was no significant difference in the rate of adverse reaction( P>0.05). The median survival time of patients and the 3-year overall survival rate were 33.0 months and 41.07%,and those in the control group were 30.0 months and 32.14%,the differences were not statistically significant between the two groups( P> 0.05). The prognosis of patients with B cell non-Hodgkin’s lymphoma was closely related to Ann Arbor stage,IPI index,B symptoms and short-term efficacy( P < 0. 05). Conclusions CHOP regimen combined with thalidomide is effective and safe in the treatment of B cell non-Hodgkin ’s lymphoma,and the long-term prognosis could be predicted by Ann Arbor stage,IPI index,B symptoms and short-term efficacy.更多还原